544 related articles for article (PubMed ID: 17416761)
1. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
2. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Brown DR; Elbasha EH; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1585-94. PubMed ID: 20530494
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.
Kim S; Arduino JM; Roberts CC; Marsico M; Liaw KL; Skjeldestad FE
Sex Transm Dis; 2011 Jul; 38(7):587-97. PubMed ID: 21301390
[TBL] [Abstract][Full Text] [Related]
4. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J;
Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
[TBL] [Abstract][Full Text] [Related]
5. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study.
Giuliano AR; Harris R; Sedjo RL; Baldwin S; Roe D; Papenfuss MR; Abrahamsen M; Inserra P; Olvera S; Hatch K
J Infect Dis; 2002 Aug; 186(4):462-9. PubMed ID: 12195372
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
7. The natural history of type-specific human papillomavirus infections in female university students.
Richardson H; Kelsall G; Tellier P; Voyer H; Abrahamowicz M; Ferenczy A; Coutlée F; Franco EL
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):485-90. PubMed ID: 12814991
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
Bao YP; Li N; Smith JS; Qiao YL
Int J STD AIDS; 2008 Feb; 19(2):106-11. PubMed ID: 18334063
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus infections and vulvar disease development.
Garland SM; Insinga RP; Sings HL; Haupt RM; Joura EA
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1777-84. PubMed ID: 19505910
[TBL] [Abstract][Full Text] [Related]
11. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
12. Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe.
Fukuchi E; Sawaya GF; Chirenje M; Magure T; Tuveson J; Ma Y; Shiboski S; Da Costa M; Palefsky J; Moscicki AB; Makunike-Mutasa R; Chipato T; Smith-McCune KK
Sex Transm Dis; 2009 May; 36(5):305-11. PubMed ID: 19295468
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
14. Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears.
Schneider A; Kirchhoff T; Meinhardt G; Gissmann L
Obstet Gynecol; 1992 May; 79(5 ( Pt 1)):683-8. PubMed ID: 1314360
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.
Franco EL; Villa LL; Sobrinho JP; Prado JM; Rousseau MC; Désy M; Rohan TE
J Infect Dis; 1999 Nov; 180(5):1415-23. PubMed ID: 10515798
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
17. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
Agarossi A; Ferrazzi E; Parazzini F; Perno CF; Ghisoni L
J Med Virol; 2009 Mar; 81(3):529-35. PubMed ID: 19152401
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
20. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.
Marais DJ; Passmore JA; Denny L; Sampson C; Allan BR; Williamson AL
J Med Virol; 2008 Jun; 80(6):953-9. PubMed ID: 18428143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
